These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1145 related articles for article (PubMed ID: 30120962)

  • 41. Synergy between amyloid-β and tau in Alzheimer's disease.
    Busche MA; Hyman BT
    Nat Neurosci; 2020 Oct; 23(10):1183-1193. PubMed ID: 32778792
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease.
    Zhang H; Wei W; Zhao M; Ma L; Jiang X; Pei H; Cao Y; Li H
    Int J Biol Sci; 2021; 17(9):2181-2192. PubMed ID: 34239348
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Direct Interaction between the β-Amyloid Core and Tau Facilitates Cross-Seeding: A Novel Target for Therapeutic Intervention.
    Tripathi T; Khan H
    Biochemistry; 2020 Feb; 59(4):341-342. PubMed ID: 31944100
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Significance of tau in the development of Alzheimer's disease].
    Takashima A
    Brain Nerve; 2010 Jul; 62(7):701-8. PubMed ID: 20675874
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches.
    Rüb U; Stratmann K; Heinsen H; Seidel K; Bouzrou M; Korf HW
    J Alzheimers Dis; 2017; 57(3):683-696. PubMed ID: 28269779
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.
    Thal DR; Attems J; Ewers M
    J Alzheimers Dis; 2014; 42 Suppl 4():S421-9. PubMed ID: 25227313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Development of Disease-modifying Therapy for Alzheimer's Disease].
    Akiyama H
    Brain Nerve; 2016 Apr; 68(4):463-72. PubMed ID: 27056864
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease.
    Watanabe K; Uemura K; Asada M; Maesako M; Akiyama H; Shimohama S; Takahashi R; Kinoshita A
    Mol Brain; 2015 Dec; 8(1):82. PubMed ID: 26637371
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in the detergent-insoluble brain proteome linked to amyloid and tau in Alzheimer's Disease progression.
    Hales CM; Dammer EB; Deng Q; Duong DM; Gearing M; Troncoso JC; Thambisetty M; Lah JJ; Shulman JM; Levey AI; Seyfried NT
    Proteomics; 2016 Dec; 16(23):3042-3053. PubMed ID: 27718298
    [TBL] [Abstract][Full Text] [Related]  

  • 50. C-Abl tyrosine kinase signaling: a new player in AD tau pathology.
    Estrada LD; Zanlungo SM; Alvarez AR
    Curr Alzheimer Res; 2011 Sep; 8(6):643-51. PubMed ID: 21605041
    [TBL] [Abstract][Full Text] [Related]  

  • 51. β-amyloid and tau drive early Alzheimer's disease decline while glucose hypometabolism drives late decline.
    Hammond TC; Xing X; Wang C; Ma D; Nho K; Crane PK; Elahi F; Ziegler DA; Liang G; Cheng Q; Yanckello LM; Jacobs N; Lin AL
    Commun Biol; 2020 Jul; 3(1):352. PubMed ID: 32632135
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model.
    Hirata-Fukae C; Li HF; Hoe HS; Gray AJ; Minami SS; Hamada K; Niikura T; Hua F; Tsukagoshi-Nagai H; Horikoshi-Sakuraba Y; Mughal M; Rebeck GW; LaFerla FM; Mattson MP; Iwata N; Saido TC; Klein WL; Duff KE; Aisen PS; Matsuoka Y
    Brain Res; 2008 Jun; 1216():92-103. PubMed ID: 18486110
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proteins recruited to exosomes by tau overexpression implicate novel cellular mechanisms linking tau secretion with Alzheimer's disease.
    Saman S; Lee NC; Inoyo I; Jin J; Li Z; Doyle T; McKee AC; Hall GF
    J Alzheimers Dis; 2014; 40 Suppl 1(Suppl 1):S47-70. PubMed ID: 24718102
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Pathological changes induced by amyloid-β in Alzheimer's disease].
    Takata K; Kitamura Y; Taniguchi T
    Yakugaku Zasshi; 2011 Jan; 131(1):3-11. PubMed ID: 21212607
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A critical analysis of the 'amyloid cascade hypothesis'.
    Armstrong RA
    Folia Neuropathol; 2014; 52(3):211-25. PubMed ID: 25310732
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Untangling amyloid-β, tau, and metals in Alzheimer's disease.
    Savelieff MG; Lee S; Liu Y; Lim MH
    ACS Chem Biol; 2013 May; 8(5):856-65. PubMed ID: 23506614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease.
    Boche D; Donald J; Love S; Harris S; Neal JW; Holmes C; Nicoll JA
    Acta Neuropathol; 2010 Jul; 120(1):13-20. PubMed ID: 20532897
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mouse models of Alzheimer's disease: the long and filamentous road.
    Phinney AL; Horne P; Yang J; Janus C; Bergeron C; Westaway D
    Neurol Res; 2003 Sep; 25(6):590-600. PubMed ID: 14503012
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Propagation of Aß pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.
    Eisele YS; Duyckaerts C
    Acta Neuropathol; 2016 Jan; 131(1):5-25. PubMed ID: 26715565
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation.
    Shin WS; Di J; Cao Q; Li B; Seidler PM; Murray KA; Bitan G; Jiang L
    Alzheimers Res Ther; 2019 Oct; 11(1):86. PubMed ID: 31627745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.